Compare PMAX & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMAX | VIVS |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 2.1M |
| IPO Year | 2024 | 2010 |
| Metric | PMAX | VIVS |
|---|---|---|
| Price | $0.48 | $0.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.2M | 656.4K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,603,000.00 |
| Revenue This Year | N/A | $228,144.28 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.82 |
| 52 Week Low | $0.20 | $0.15 |
| 52 Week High | $4.81 | $3.40 |
| Indicator | PMAX | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 33.87 | 29.48 |
| Support Level | $0.28 | N/A |
| Resistance Level | $2.69 | $0.30 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 6.31 | 8.92 |
Powell Max Ltd operates as a financial communications platform supporting listed companies and IPO applicants throughout the capital markets lifecycle. Substantially all of the company's revenue is generated from Hong Kong. The group focused on supporting the disclosure, reporting, and transaction needs of corporate clients and their advisors. Its mission is to combine industry knowledge, execution capabilities, and a commitment to service to deliver accurate, timely, and reliable solutions for customers.
VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.